CEO and Portfolio Manager
A seasoned executive with more than 30 years of diverse experience in the life sciences, healthcare, technology and private equity industries, Michael Holder leads CLI’s broad strategic vision and overall operations including product development, corporate strategy, sales, business execution, M&A activities, and fundraising transactions. Michael also leads and is responsible for development and management of CLI’s acquisitions and other strategic transactions in the longevity healthcare eco-system.
As former Chairman and CEO of Organ Transport Systems Inc., a medical technology company that is a leader in heart preservation and transport, Michael was responsible for developing the LifeCradle® Heart Perfusion System, a heart transportation device that nourishes and preserves the organ during transport prior to transplantation. His work in product development, research, regulatory compliance, intellectual property, business development, fundraising, and governance included completing a strategic acquisition, recruiting high-level board members, raising $12 million in equity capital in multiple investment rounds and developing and maintaining prominent international partnerships.
Michael’s prior experience also includes service as vice president of sales, operations, and finance for Premier Inc., a publicly traded hospital group purchasing organization; chief financial officer of Clarkston Potomac Group Inc., a leading enterprise software integration and technology firm; and chief financial officer of Beacon Eye Institute, a publicly traded provider of laser vision correction services until its sale to a strategic buyer. Michael also served as an executive in the Sam Walton family private equity fund, Heartland Capital Partners LP. He has also served on boards of numerous companies, including Organ Transport Systems Inc., Beacon Eye Centers Inc., Cypher LLC, and Loyalty Management Group Inc.
Michael holds an MBA from the Wharton School at the University of Pennsylvania and a B.S. in business administration from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill. He previously obtained his certification as a Certified Public Accountant in the State of Texas and is a member of the National Association of Corporate Directors.
Chief Operations and Scientific Officer
With more than 35 years of experience and demonstrated success in the biopharmaceutical drug development and investment sectors, Brian Huber leads the scientific, clinical, and operational activities at CLI.
As managing director and VP at Quintiles/IQVIA, Brian’s 10-year service included responsiblity for drug investment, risk-based investments, and partnerships, and he managed key pharma accounts across the clinical and commercial business sectors, delivering clinical oversight to drive efficiency, risk mitigation, clinical outcomes, and profitability. His prior experience over the course of two decades with GlaxoSmithKline and the National Cancer Institute of the National Institutes of Health and Cato BioVentures ranged from managing drug discovery and clinical drug development portolios to achieving maximal patient value and company ROI and developing and managing key partnerships for financial growth, clinical delivery and execution, and profitability, to identifying, structuring, and managing innovative clinical investments involving biopharmaceutical companies, core GP investors and third-party syndicated capital sources.
Brian holds a Ph.D. in pharmacology from The George Washington University and a B.S. and M.S. from Villanova University. He is also Board Certified in Clinical Pharmacology and has completed residency programs in Advanced Leadership from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and at the London Business School. Brian has authored over 60 peer-reviewed publications, is on 12 issued patents, and has published a number of books. He holds adjunct academic positions at Duke University and The George Washington University.
Dr. Elaine Chin, who serves as an advisor to CLI, is a seasoned medical doctor, health coach, and bestselling author. Throughout her career, she has worked to help people live longer, and have more rewarding, disease- and disability-free lives. She is a North American thought leader and recognized expert in personalized medicine, which leverages biometric and digital platform technologies – along with predictive analytics – to improve the health and performance of individuals.
Elaine is the founder and medical director of Innovation Health Group, a provider of enterprise wellness programs delivered on a virtual platform, and Executive Health Centre, a premiere personalized medicine practice in Toronto, Canada. In January 2018, she joined the Good Housekeeping Magazine team as its health and wellness medical consultant. As a monthly column contributor, Elaine reaches more than 30 million readers monthly on health and wellness topics important to this brand’s print and online audiences.
Most recently, Elaine served as chief wellness officer at TELUS Communications, with a focus on delivering world-class wellness programs to Canadians by integrating digital health technology and precision medicine. She currently serves as Heath Leader-In-Residence at the Odette School of Business at the University of Windsor, and she is part of an academic team that drives results at the World Health Innovation Network (WIN).
Elaine has written Lifelines: Unlocking the Secret of Your Telomeres for a Longer, Healthier Life, which appeared on Canada’s Globe and Mail’s Top 10 Best Seller List. She received her medical degree from the University of Toronto, Canada, and her MBA from the same university’s Rotman School of Management
As the Editorial Director for CLI, Erin curates all content for the website and associated publications. She has extensive experience in writing, launching, and leading healthcare publications, such as Health Information Compliance Alert, SuperCoder (https://www.supercoder.com) and Eye Care Leaders magazine. Erin’s interest in scientific and medical writing goes back to her time as a teaching fellow at UNC-CH, where she taught writing classes tailored for biology undergrads and med students. She also worked with molecular biologists to write then-new curricula for regional university students and to secure the funding necessary all biology majors in North Carolina to have access to molecular biology lab experience as part of their education.
Erin holds a Ph.D. in English from the University of North Carolina at Chapel Hill and a B.A. in English from the University of Texas at Austin.